Pharmaceuticals/Chemicals

Clenbuterol (Oral)

Also called Clen

Clenbuterol is sought for fat loss and a leaner look, but feeling stimulated is not proof of useful fat loss. Heart effects can be serious, and a recent controlled study found worse cardiorespiratory fitness despite lean-mass gains.

Open the plotter Sources

Dosage & duration

Published research · oral clenbuterol · supervised study

2025 crossover-study exposure

Published example · product-specific

Dose: 80 mcg total per day
How often: Daily (four 20 mcg tablets total)
How long: 2-week treatment period

Research exposure, not a suggested starting dose, safe cycle or escalation plan.

Sources: 1 · 2

More quick facts

Why people seek it: Cutting and fat-loss goals; Sources : 1 · 2
Performance trade-off: More lean mass is not more fitness; Sources : 1 · 2
Key units: Micrograms, not milligrams; Sources : 1 · 2

Cutting claims

Stimulation does not measure fat loss

The short trial

Compared with placebo, an 11-man, two-week trial found more lean mass, no significant fat-mass change and lower cardiorespiratory fitness.
Heart effects

Published toxicity includes a racing heart, heart injury and low potassium.

Micrograms and milligrams differ by 1,000-fold; confusing them is a serious error. Sources and context

Why do people use it during a cut?

Its stimulant-like effects and fat-loss reputation attract physique users. Reported experiences mix changes in diet, training and other drugs, so the amount of weight lost cannot be attributed cleanly to clenbuterol.

What did controlled research find?

In a two-week trial in 11 healthy men, clenbuterol increased lean mass but did not significantly change fat mass compared with placebo. Cardiorespiratory fitness fell. These short-study findings do not support treating a stimulated feeling as proof of fat loss or better endurance.

What dose and cycle claims miss

The visible example is supervised research. Online two-weeks-on schedules and escalating doses do not establish protection from heart effects. Microgram notation must remain explicit; milligrams are a different scale.

When symptoms need action

Chest pain, fainting, breathing difficulty or a persistent racing/irregular heartbeat warrant urgent assessment. Published toxicity includes heart injury and low potassium. Do not interpret a plot as clearance to exercise through symptoms.

Model details: Clenbuterol (Oral) · relative timing

Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.

Shows a relative timing scenario; absolute blood concentrations are not calibrated.

Timing assumptions and sources

Yamamoto 1985 total unchanged parent; do not substitute newer R-enantiomer peaks.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used: 35 hours
Absorption half-life assumed: 0.3786961 hours
Reference amount for the relative scale: 1 mg

The faster rate is inferred to match the 2.5 h source-scoped peak time; absorption half-life 0.3786961309490016 h is a mathematical shape parameter, not separately measured.
A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
A peak-normalized 35 h curve predicts~0.962 ng/mL after 40 mcg q 12 h vs reported 0.5–0.6 plateau; source constraints conflict.
0.04 mg=40 mcg; no extra 90% F.
R-enantiomer and racemate values cannot be mixed.

Yamamoto et al 1985: plasma and urine clenbuterol
20/40/80 mcg oral=>0.1/0.2/0.35 ng/mL; peakwithin 2.5 h, h 35;40 mcg twice daily reaches 0.5–0.6 ng/mL plateau.
Original journal article, Yamamoto 1985
Same monocompound human PK observations; rat/rabbit arms must be separated.
Lodeweyckx 2024 clenbuterol
Newer assay reports R-enantiomer concentrations, not total racemate.

clenbuterol-relative-timing-2026-10 · version 1

Safety and interaction notes Read the limitations and discuss clinical questions with a professional

Aromatizes: No

Human toxicity reports document rapid heartbeat, low potassium and heart-muscle injury. A controlled trial also found reduced cardiorespiratory fitness; the plot cannot identify safe exposure.

Common questions

Do shakes or a racing heart mean clenbuterol is burning more fat?

No. A stimulant-like feeling is not a measurement of fat loss. People report both positive cutting experiences and disruptive side effects; they cannot establish safety or separate the drug from diet and other compounds.

Does a two-week study prove a two-week cycle is safe?

No. A study duration and an individual safety guarantee are different things.

Sources Labels, studies and notes behind this guide

Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.

Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.

Notes on the quick facts

Why people seek it: Weight-loss marketing is different from an approved personal treatment plan.
Performance trade-off: In an 11-man, two-week trial, lean mass rose, fat mass did not significantly change and cardiorespiratory fitness fell.
Key units: Confusing mcg with mg creates a thousand-fold error.

1. Clenbuterol randomized crossover study
Primary 2025 randomized crossover trial in 11 healthy men: 80 mcg total/day for two weeks; lean-mass gain, no significant fat-mass change versus placebo, and reduced cardiorespiratory fitness. Not a safe fat-loss prescription.
2. Clenbuterol cardiac toxicity case
Case and clinical discussion: tachycardia, myocardial injury, low potassium; dose-specific overdose does not establish lower-dose safety.
3. Yamamoto et al 1985: plasma and urine clenbuterol
20/40/80 mcg oral=>0.1/0.2/0.35 ng/mL; peakwithin 2.5 h, h 35;40 mcg twice daily reaches 0.5–0.6 ng/mL plateau.
4. Original journal article, Yamamoto 1985
Same monocompound human PK observations; rat/rabbit arms must be separated.
5. Lodeweyckx 2024 clenbuterol
Newer assay reports R-enantiomer concentrations, not total racemate.
6. Ambroxol/clenbuterol tablet pharmacokinetics study
Abstract: nine healthy Chinese volunteers; combination-tablet single/repeat dosing and accumulation. Not a fat-loss efficacy or safety study.
7. FDA: unapproved clenbuterol products
US regulatory status: clenbuterol not approved for human use.
8. Hostrup et al. 2025, controlled clenbuterol trial
Original abstract/full text checked: 11 healthy men, two-week crossover periods; lean mass increased, no fat-mass effect, maximal oxygen uptake and exercise capacity declined. Not long-term safety or interaction evidence.
9. Moesgaard et al. 2026, clenbuterol with resistance training
Original abstract checked; published 12 September 2026. Thirty-two men/women completed eight-week resistance training with drug or placebo, followed by detraining/retraining. Lean mass/strength benefits during exposure, no additional fat-mass decrease; not a safe regimen recommendation.

Steroid and Medication Interactions: Combinations to Check

3 min read

Related compounds and examples

Related compounds

Estradiol Topical (EstroGel)

Estradiol gel is used to ease menopausal hot flushes and other low-estrogen symptoms without a pill or injection. The practical choices are the exact pump product, the daily skin routine and whether a separate progestogen is needed.

Estradiol Cypionate

Estradiol cypionate provides estrogen through an injection rather than a daily pill or gel. It is used for low-estrogen symptoms and in feminizing hormone care; the reason for treatment determines the dose and schedule.

Estradiol Valerate

Estradiol valerate injections are used for estrogen replacement and feminizing hormone care. Readers usually want a manageable injection routine and fewer swings between doses. The amount, interval and reason for treatment matter more than chasing a high peak.